Skip to main content

Table 2 Univariate analysis of genetic mutations and recurrence survival rate

From: Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing

Gene Alterations (%) Total patients (n = 58) BCG subgroup (n = 46)
   P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI)
NEB 5.2 0.001 17.307 (3.305–90.639) 0.001 21.213 (3.466–129.823)
MLH1 5.2 0.011 18.580 (1.933–178.630) NA NA
CDKN1B 3.4 0.011 18.580 (1.933–178.630) NA NA
FGF12 1.7 0.011 18.580 (1.933–178.630) 0.012 21.995 (1.994–242.587)
NKX2_1 1.7 0.011 18.580 (1.933–178.630) NA NA
RET 1.7 0.011 18.580 (1.933–178.630) NA NA
SDHB 1.7 0.011 18.580 (1.933–178.630) NA NA
TAF1 1.7 0.011 18.580 (1.933–178.630) 0.012 14.493 (1.507–139.347)
EPHB1 3.4 0.019 13.794 (1.542–123.422) NA NA
PIK3C3 1.7 0.019 13.794 (1.542–123.422) NA NA
ZNF703 1.7 0.019 13.794 (1.542–123.422) NA NA
PALB2 3.4 0.028 5.421 (1.195–24.597) 0.056 8.100 (0.946–69.384)
GATA3 5.2 0.024 6.140 (1.263–29.846) 0.178 4.394 (0.510–37.818)
FGFR1 5.2 0.029 10.924 (1.276–93.521) 0.021 14.493 (1.507–139.347)
MAX 1.7 0.029 10.924 (1.276–93.521) 0.021 14.493 (1.507–139.347)
SDHC 12.1 0.074 3.917 (0.877–17.507) 0.003 11.892 (2.272–62.246)
MTOR 5.2 0.052 4.442 (0.989–19.956) 0.024 6.301 (1.278–31.072)
RAF1 5.2 0.042 8.986 (1.082–74.659) 0.034 10.686 (1.194–95.634)
RECQL4 1.7 0.042 8.986 (1.082–74.659) 0.034 10.686 (1.194–95.634)
SDHAF2 1.7 0.042 8.986 (1.082–74.659) 0.034 10.686 (1.194–95.634)
  1. Mutated genes significantly correlated with prognosis are shown. BCG: Bacillus Calmette–Guérin; CI: confidence interval; n: number; NA: not available